Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Evolution of platelet functions in cirrhotic patients undergoing liver transplantation: A prospective exploration over a month.

Eyraud D, Suner L, Dupont A, Bachelot-Loza C, Smadja DM, Helley D, Bertil S, Gostian O, Szymezak J, Loncar Y, Puybasset L, Lebray P, Vezinet C, Vaillant JC, Granger B, Gaussem P.

PLoS One. 2018 Aug 2;13(8):e0200364. doi: 10.1371/journal.pone.0200364. eCollection 2018.

2.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Jul 30. doi: 10.1158/1078-0432.CCR-18-1045. [Epub ahead of print]

PMID:
30061359
3.

[Antiplatelet agents and transfusion].

Gaussem P, Martin AC, Belleville-Rolland T, Helley D, Bachelot-Loza C, Godier A.

Transfus Clin Biol. 2017 Sep;24(3):160-165. doi: 10.1016/j.tracli.2017.05.014. Epub 2017 Jun 20. Review. French.

PMID:
28645644
4.

Prospective observational study of the effect of dual antiplatelet therapy with tranexamic acid treatment on platelet function and bleeding after cardiac surgery.

Amour J, Garnier M, Szymezak J, Le Manach Y, Helley D, Bertil S, Ouattara A, Riou B, Gaussem P.

Br J Anaesth. 2016 Dec;117(6):749-757.

5.

Low-Molecular-Weight Fucoidan Induces Endothelial Cell Migration via the PI3K/AKT Pathway and Modulates the Transcription of Genes Involved in Angiogenesis.

Bouvard C, Galy-Fauroux I, Grelac F, Carpentier W, Lokajczyk A, Gandrille S, Colliec-Jouault S, Fischer AM, Helley D.

Mar Drugs. 2015 Dec 18;13(12):7446-62. doi: 10.3390/md13127075.

6.

Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer.

Mondini M, Nizard M, Tran T, Mauge L, Loi M, Clémenson C, Dugue D, Maroun P, Louvet E, Adam J, Badoual C, Helley D, Dransart E, Johannes L, Vozenin MC, Perfettini JL, Tartour E, Deutsch E.

Mol Cancer Ther. 2015 Jun;14(6):1336-45. doi: 10.1158/1535-7163.MCT-14-1015. Epub 2015 Apr 1.

7.

[Thrombopathy induced by selective serotonin reuptake inhibitors: a case report].

Ben Said M, Amar L, Smadja D, Rivet N, Bertil S, Fischer AM, Helley D, Gaussem P.

Ann Biol Clin (Paris). 2014 Sep-Oct;72(5):607-11. doi: 10.1684/abc.2014.0997. French.

8.

Endothelial podosome rosettes regulate vascular branching in tumour angiogenesis.

Seano G, Chiaverina G, Gagliardi PA, di Blasio L, Puliafito A, Bouvard C, Sessa R, Tarone G, Sorokin L, Helley D, Jain RK, Serini G, Bussolino F, Primo L.

Nat Cell Biol. 2014 Oct;16(10):931-41, 1-8. doi: 10.1038/ncb3036. Epub 2014 Sep 14.

9.

Tie2-dependent deletion of α6 integrin subunit in mice reduces tumor growth and angiogenesis.

Bouvard C, Segaoula Z, De Arcangelis A, Galy-Fauroux I, Mauge L, Fischer AM, Georges-Labouesse E, Helley D.

Int J Oncol. 2014 Nov;45(5):2058-64. doi: 10.3892/ijo.2014.2631. Epub 2014 Sep 1.

PMID:
25176420
10.

Circulating endothelial cells as markers of endothelial dysfunction during hematopoietic stem cell transplantation for pediatric primary immunodeficiency.

Touzot F, Moshous D, Cros G, Frange P, Chomton M, Frémond ML, Neven B, Cavazzana M, Fischer A, Blanche S, Helley D.

J Allergy Clin Immunol. 2014 Nov;134(5):1203-6. doi: 10.1016/j.jaci.2014.05.039. Epub 2014 Jul 16. No abstract available.

PMID:
25042984
11.

Control of the adaptive immune response by tumor vasculature.

Mauge L, Terme M, Tartour E, Helley D.

Front Oncol. 2014 Mar 28;4:61. doi: 10.3389/fonc.2014.00061. eCollection 2014. Review.

12.

The in vitro and in vivo effects of a low-molecular-weight fucoidan on the osteogenic capacity of human adipose-derived stromal cells.

Pereira J, Portron S, Dizier B, Vinatier C, Masson M, Sourice S, Galy-Fauroux I, Corre P, Weiss P, Fischer AM, Guicheux J, Helley D.

Tissue Eng Part A. 2014 Jan;20(1-2):275-84. doi: 10.1089/ten.TEA.2013.0028. Epub 2013 Oct 31.

PMID:
24059447
13.

Endothelial colony-forming cells from patients with paroxysmal nocturnal haemoglobinuria are not PIGA mutated.

Gandrille S, Peffault de Latour R, Levionnois E, Rodriguez-Otero P, Galy-Fauroux I, Zemori L, Abbes S, Petropoulou AD, Socié G, Fischer AM, Helley D.

Br J Haematol. 2013 Apr;161(1):144-7. doi: 10.1111/bjh.12193. Epub 2013 Jan 7. No abstract available.

PMID:
23294396
14.

Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy.

Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D, Socié G.

Br J Haematol. 2013 Apr;161(2):279-80. doi: 10.1111/bjh.12202. Epub 2013 Jan 7. No abstract available.

PMID:
23294015
15.

Tie2-dependent knockout of α6 integrin subunit in mice reduces post-ischaemic angiogenesis.

Bouvard C, De Arcangelis A, Dizier B, Galy-Fauroux I, Fischer AM, Georges-Labouesse E, Helley D.

Cardiovasc Res. 2012 Jul 1;95(1):39-47. doi: 10.1093/cvr/cvs153. Epub 2012 Apr 19.

PMID:
22517984
16.

Marine polysaccharides: a source of bioactive molecules for cell therapy and tissue engineering.

Senni K, Pereira J, Gueniche F, Delbarre-Ladrat C, Sinquin C, Ratiskol J, Godeau G, Fischer AM, Helley D, Colliec-Jouault S.

Mar Drugs. 2011;9(9):1664-81. doi: 10.3390/md9091664. Epub 2011 Sep 23. Review.

17.

Antiphospholipid antibodies in patients with paroxysmal nocturnal haemoglobinuria receiving eculizumab.

Darnige L, Peffault de Latour R, Zemori L, Socié G, Fischer AM, Helley D; French Society of Haematology.

Br J Haematol. 2011 Jun;153(6):789-91. doi: 10.1111/j.1365-2141.2011.08665.x. Epub 2011 Apr 4. No abstract available.

PMID:
21457219
18.

[Thrombocytopenia associated with iron deficiency: a rare differential diagnosis of auto-immune thrombocytopenic purpura].

Chaker S, Very S, Helley D, Gaussem P, Pouchot J, Darnige L, Fischer AM, Capron L, Arlet JB.

Rev Med Interne. 2010 Sep;31(9):631-6. doi: 10.1016/j.revmed.2010.01.012. Epub 2010 Jun 2. French.

PMID:
20627480
19.

alpha6-integrin subunit plays a major role in the proangiogenic properties of endothelial progenitor cells.

Bouvard C, Gafsou B, Dizier B, Galy-Fauroux I, Lokajczyk A, Boisson-Vidal C, Fischer AM, Helley D.

Arterioscler Thromb Vasc Biol. 2010 Aug;30(8):1569-75. doi: 10.1161/ATVBAHA.110.209163. Epub 2010 May 27.

PMID:
20508204
20.

Perfusion defects after pulmonary embolism: risk factors and clinical significance.

Sanchez O, Helley D, Couchon S, Roux A, Delaval A, Trinquart L, Collignon MA, Fischer AM, Meyer G.

J Thromb Haemost. 2010 Jun;8(6):1248-55. doi: 10.1111/j.1538-7836.2010.03844.x. Epub 2010 Mar 17.

21.

Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies.

Duval A, Helley D, Capron L, Youinou P, Renaudineau Y, Dubucquoi S, Fischer AM, Hachulla E.

Rheumatology (Oxford). 2010 Jun;49(6):1049-55. doi: 10.1093/rheumatology/keq041. Epub 2010 Mar 7.

PMID:
20211868
22.

Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

Helley D, de Latour RP, Porcher R, Rodrigues CA, Galy-Fauroux I, Matheron J, Duval A, Schved JF, Fischer AM, Socié G; French Society of Hematology.

Haematologica. 2010 Apr;95(4):574-81. doi: 10.3324/haematol.2009.016121. Epub 2010 Jan 15.

23.

Platelet microparticle levels: a biomarker of thromboangiitis obliterans (Buerger's disease) exacerbation.

Darnige L, Helley D, Fischer AM, Emmerich J, Smadja DM, Fiessinger JN.

J Cell Mol Med. 2010 Jan;14(1-2):449-51. doi: 10.1111/j.1582-4934.2009.00928.x. Epub 2009 Oct 10. No abstract available.

24.

Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.

Medioni J, Banu E, Helley D, Scotte F, Fournier L, Mejean A, Chedid A, Azizi M, Andrieu JM, Oudard S.

Eur Urol. 2009 Jul;56(1):207-11; quiz 211. doi: 10.1016/j.eururo.2009.01.001. Epub 2009 Jan 13.

PMID:
19157688
25.

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib.

Billemont B, Medioni J, Taillade L, Helley D, Meric JB, Rixe O, Oudard S.

Br J Cancer. 2008 Nov 4;99(9):1380-2. doi: 10.1038/sj.bjc.6604709. Epub 2008 Oct 7.

26.

Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy.

Helley D, Banu E, Bouziane A, Banu A, Scotte F, Fischer AM, Oudard S.

Eur Urol. 2009 Sep;56(3):479-84. doi: 10.1016/j.eururo.2008.06.038. Epub 2008 Jun 20.

PMID:
18585841
27.

Effect of low molecular weight fucoidan and low molecular weight heparin in a rabbit model of arterial thrombosis.

Durand E, Helley D, Al Haj Zen A, Dujols C, Bruneval P, Colliec-Jouault S, Fischer AM, Lafont A.

J Vasc Res. 2008;45(6):529-37. doi: 10.1159/000129687. Epub 2008 May 7.

PMID:
18463418
28.

Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances in vitro angiogenesis with up-regulation of integrin alpha(6).

Smadja DM, Bièche I, Helley D, Laurendeau I, Simonin G, Muller L, Aiach M, Gaussem P.

J Cell Mol Med. 2007 Sep-Oct;11(5):1149-61.

29.

Neoangiogenesis induced by progenitor endothelial cells: effect of fucoidan from marine algae.

Boisson-Vidal C, Zemani F, Caligiuri G, Galy-Fauroux I, Colliec-Jouault S, Helley D, Fischer AM.

Cardiovasc Hematol Agents Med Chem. 2007 Jan;5(1):67-77. Review.

PMID:
17266549
30.

[Prognostic factors in chronic lymphocytic leukaemia: contribution of recent biological markers].

Evrard S, Gaussem P, Helley D, Darnige L.

Ann Biol Clin (Paris). 2005 Nov-Dec;63(6):589-97. Review. French.

31.

Effect of an oversulfated exopolysaccharide on angiogenesis induced by fibroblast growth factor-2 or vascular endothelial growth factor in vitro.

Matou S, Colliec-Jouault S, Galy-Fauroux I, Ratiskol J, Sinquin C, Guezennec J, Fischer AM, Helley D.

Biochem Pharmacol. 2005 Mar 1;69(5):751-9. Epub 2005 Jan 12.

PMID:
15710353
32.
33.

[Microbial polysaccharides of marine origin and their potential in human therapeutics].

Colliec-Jouault S, Zanchetta P, Helley D, Ratiskol J, Sinquin C, Fischer AM, Guezennec J.

Pathol Biol (Paris). 2004 Apr;52(3):127-30. French.

PMID:
15063931
34.
35.

Effect of low-molecular-weight fucoidan on experimental arterial thrombosis in the rabbit and rat.

Colliec-Jouault S, Millet J, Helley D, Sinquin C, Fischer AM.

J Thromb Haemost. 2003 May;1(5):1114-5. No abstract available.

36.

A fucosylated chondroitin sulfate from echinoderm modulates in vitro fibroblast growth factor 2-dependent angiogenesis.

Tapon-Bretaudière J, Chabut D, Zierer M, Matou S, Helley D, Bros A, Mourão PA, Fischer AM.

Mol Cancer Res. 2002 Dec;1(2):96-102.

37.

Effect of fucoidan on fibroblast growth factor-2-induced angiogenesis in vitro.

Matou S, Helley D, Chabut D, Bros A, Fischer AM.

Thromb Res. 2002 May 15;106(4-5):213-21.

PMID:
12297128
38.

Red blood cells from patients with homozygous sickle cell disease provide a catalytic surface for factor Va inactivation by activated protein C.

Bezeaud A, Venisse L, Helley D, Trichet C, Girot R, Guillin MC.

Br J Haematol. 2002 May;117(2):409-13.

PMID:
11972526
39.

Characterization, chemical modifications and in vitro anticoagulant properties of an exopolysaccharide produced by Alteromonas infernus.

Colliec Jouault S, Chevolot L, Helley D, Ratiskol J, Bros A, Sinquin C, Roger O, Fischer AM.

Biochim Biophys Acta. 2001 Oct 3;1528(2-3):141-51.

PMID:
11687301
40.

Factors V leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis.

Meyer G, Emmerich J, Helley D, Arnaud E, Nicaud V, Alhenc-Gelas M, Aiach M, Fischer A, Sors H, Fiessinger JN.

Am J Med. 2001 Jan;110(1):12-5.

PMID:
11152859
41.

Prevalence of the prothrombin gene 20210A mutation in thrombophilic and healthy Algerian subjects.

Helley D, Chafa O, Yaker NL, Reghis A, Fischer AM.

Thromb Haemost. 1999 Nov;82(5):1554-5. No abstract available.

PMID:
10595654
42.

Detection of phosphatidylserine surface exposure on human erythrocytes using annexin V-ferrofluid.

Geldwerth D, Helley D, de Jong K, Sabolovic' D, Sestier C, Roger J, Pons JN, Freyssinet JM, Devaux PF, Kuypers FA.

Biochem Biophys Res Commun. 1999 Apr 29;258(1):199-203.

PMID:
10222260
43.
44.

Prospective evaluation of the prevalence of factor V Leiden mutation in portal or hepatic vein thrombosis.

Denninger MH, Helley D, Valla D, Guillin MC.

Thromb Haemost. 1997 Oct;78(4):1297-8. No abstract available.

PMID:
9365003
45.

Polymorphism in exon 10 of the human coagulation factor V gene in a population at risk for sickle cell disease.

Helley D, Besmond C, Ducrocq R, da Silva F, Guillin MC, Bezeaud A, Elion J.

Hum Genet. 1997 Aug;100(2):245-8.

PMID:
9254858
46.

Phosphatidylserine exposure and aminophospholipid translocase activity in Rh-deficient erythrocytes.

Geldwerth D, Cherif-Zahar B, Helley D, Gane P, Freyssinet JM, Colin Y, Devaux PF, Cartron JP.

Mol Membr Biol. 1997 Jul-Sep;14(3):125-32.

PMID:
9394292
47.

Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia.

Helley D, Eldor A, Girot R, Ducrocq R, Guillin MC, Bezeaud A.

Thromb Haemost. 1996 Sep;76(3):322-7.

PMID:
8883264
48.

Functional consequences of the Ser334-->Pro mutation in a human factor X variant (factor XMarseille).

Bezeaud A, Miyata T, Helley D, Zeng YZ, Kato H, Aillaud MF, Juhan-Vague I, Guillin MC.

Eur J Biochem. 1995 Nov 15;234(1):140-7.

Supplemental Content

Loading ...
Support Center